Bendamustine Hydrochloride, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
Status:
Completed
Trial end date:
2018-11-17
Target enrollment:
Participant gender:
Summary
This phase II trial studies side effects and how well bendamustine hydrochloride, bortezomib,
and dexamethasone work in treating patients with newly diagnosed multiple myeloma. Drugs used
in chemotherapy, such as bendamustine hydrochloride and dexamethasone, work in different ways
to stop the growth of cancer cells, either by killing the cells, by stopping them from
dividing, or by stopping them from spreading. Bortezomib may stop the growth of cancer cells
by blocking some of the enzymes needed for cell growth. Giving bendamustine hydrochloride
with bortezomib and dexamethasone may kill more cancer cells.
Phase:
Phase 2
Details
Lead Sponsor:
Sidney Kimmel Cancer Center at Thomas Jefferson University